HUANG He,ZHOU Shuping,GUO Wenjian, et al. Effect of bufalin and histone deacetylase inhibitor SAHA in multiple myeloma cells[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2018, 48(10): 750-753,758.
Abstract：Objective: To investigate bufalin combined with histone deacetylase (HDAC) inhibitor SAHA on growth inhibition and apoptosis of multiple myeloma cell lines. Methods: CCK-8 and flow cytometry (RH-123, PI staining) assay were used to assess the effects of bufalin on induction of apoptosis in multiple myeloma (MM) cells. Then, CCK-8 assay was carried out to examine the effects of SAHA in single or in combination of bufalin, on the inhibition of proliferation in MM cells. Results: Bufalin exerted remarkable effects on growth suppression of multiple myeloma cells NCI-H929, U266 and CZ-1, with the concentration of IC50 about 10-20 nmol/L. Cell cycle distribution was determined by flow cytometry analysis of DNA content, indicating bufalin mainly caused S and G2-M arrest in H929, U266 and RPMI8226 cells. Furthermore, it was investigated that bufalin could induce MM cells apoptosis through mitochondrial damage and SAHA could inhibit the growth of MM cells. When H929 cells treated with these two agents for 48 h, it was found 10 nmol/L bufalin decreased about 30% viability of cells at various concentrations of SAHA, showing statistical difference when compared with these drugs in single use. Conclusion: Bufalin as well as SAHA exhibited anti-MM cells by suppression of cellular proliferation and the induction of apoptosis. And the cytocidal effects of bufalin and SAHA were significantly enhanced when the two agents were in combination even at lower concentrations.
[1] PALUMBO A, ANDERSON K. Multiple myeloma[J]. N Engl J Med, 2011, 364(11): 1046-1060.
[2] MAHINDRA A, LAUBACH J, RAJE N, et al. Latest advances and current challenges in the treatment of multiple myeloma[J]. Nat Rev Clin Oncol, 2012, 9(3): 135-143.
[3] MOREAU P, TOUZEAU C. Multiple myeloma: from front-line to relapsed therapies[M]. Am Soc Clin Oncol Educ Book, 2015: e504-511.
[4] MAES K, MENU E, VAN VALCKENBORGH E, et al. Epigenetic modulating agents as a new therapeutic approach in multiple myeloma[J]. Cancers (Basel), 2013, 5(2): 430-461.
[5] LAUBACH J P, VOORHEES P M, HASSOUN H, et al. Current strategies for treatment of relapsed/refractory multiple myeloma[J]. Expert Rev Hematol, 2014, 7(1): 97-111.
[6] ZHANG L, NAKAYA K, YOSHIDA T, et al. Induction by bufalin of differentiation of human leukemia cells HL60, U937, and ML1 toward macrophage/monocyte-like cells and its potent synergistic effect on the differentiation of human leukemia cells in combination with other inducers[J]. Cancer Res, 1992, 52(17): 4634-4641.
[7] CHEN A, YU J, ZHANG L, et al. Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells[J]. Biotechnol Lett, 2009, 31(4): 487-494.
[8] HUANG H, CAO Y, WEI W, et al. Targeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells[J]. PLoS One, 2013, 8 (6): e66130.
[9] LANE A A, CHABNER B A. Histone deacetylase inhibitors in cancer therapy[J]. J Clin Oncol, 2009, 27(32): 5459-5468.
[10] KAUFMAN J L, FABRE C, LONIAL S, et al. Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy[J]. Clin Lymphoma Myeloma Leuk, 2013, 13(4): 370-376.
[11] MITSIADES N, MITSIADES C S, RICHARDON P G, et al.
Molecular sequelae of histone deacetylase inhibition in human malignant B cells[J]. Blood, 2003, 101(10): 4055-4062.
